AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,511 AI briefs of material SEC Form 8-K filings by 4,787 companies: 2,125 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,511every one kept
Companies4,787with at least one brief
Recent filings2,125filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
- Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
- Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
- USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
- Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
Read the filing on SEC.gov ↗
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
- Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
- Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
- Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
- Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Read the filing on SEC.gov ↗
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
- Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
- GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
- Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
- Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
Read the filing on SEC.gov ↗
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
- Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
- Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
- Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
- Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Read the filing on SEC.gov ↗
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
- Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
- Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
- Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
- Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
Read the filing on SEC.gov ↗
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
- Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
- Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
- Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
- October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
Read the filing on SEC.gov ↗
RB Global reported third-quarter 2026 results with revenue up 17% year over year to $1.3 billion and net income up 47% to $140.2 million, helped by a one-time $18.2 million excise tax refund. The company raised its full-year 2026 GTV growth outlook to 14% to 15% from 9% to 11% and narrowed its adjusted EBITDA range to $1,525 million to $1,545 million from $1,495 million to $1,545 million, while also declaring a $0.33 quarterly dividend.
- Diluted EPS was $0.70, up 63%; diluted adjusted EPS was $1.03, up 11%
- Full-year 2026 GTV growth outlook raised to 14% to 15% from 9% to 11%; adjusted EBITDA low end raised to $1,525 million
- Repurchased about 3.9 million shares for $350.0 million in the quarter; $500.0 million remained under the NCIB as of September 30, 2026
- Quarterly dividend of $0.33 per share payable December 17, 2026, to holders of record November 25, 2026
Read the filing on SEC.gov ↗
Air Industries Group reported results for the three and nine months ended September 30, 2026, in a press release furnished under Item 2.02. Third-quarter net sales rose 41.1% and the company swung to net income from a loss a year earlier, though results include merger-related costs tied to its pending merger with Tenax Aerospace Acquisition, LLC.
- Q3 2026 net sales were $14.6 million, up from $10.3 million in Q3 2025; net income was $946,000 versus a net loss of $44,000.
- Nine-month net sales were $38.2 million, up 8.7%, and the net loss narrowed to $902,000 from $1.5 million.
- Q3 operating costs included $539,000 of stock compensation and merger-related expenses, with $503,000 of merger-related expense.
- The company cited October 2026 net sales of about $5.6 million and firm customer orders in backlog of $95.4 million.
Read the filing on SEC.gov ↗
AN2 Therapeutics reported third-quarter 2026 results, with net loss narrowing to $8.0 million from $9.4 million a year earlier as research and development and general and administrative expenses declined. The company reported $80.2 million in cash, cash equivalents and investments as of September 30, 2026, and projects that this will fund operations into 2029 under its current plan.
- Q3 2026 net loss was $8.0 million ($0.17 per share), versus $9.4 million ($0.31 per share) in Q3 2025.
- R&D expenses were $5.7 million, down from $7.0 million, and G&A expenses were $2.9 million, down from $3.0 million.
- Cash, cash equivalents and investments totaled $80.2 million at September 30, 2026, which the company projects will sustain operations into 2029.
- Global Phase 2 study of oral epetraborole in polycythemia vera is cleared in all planned jurisdictions, with enrollment expected to begin by year-end 2026.
Read the filing on SEC.gov ↗
Foghorn Therapeutics reported third-quarter 2026 net income of $58.2 million, compared with a net loss of $15.8 million a year earlier, on collaboration revenue of $83.5 million, up from $8.2 million. Most of the revenue increase came from a $74.1 million cumulative catch-up adjustment tied to updated estimated future costs for ending the FHD-909 and SMARCA2 selective degrader programs, so the result is largely a one-time accounting effect.
- Diluted earnings per share were $0.80, compared with a loss of $0.25 per share in the prior-year quarter.
- Research and development expenses fell to $18.8 million from $20.0 million, and general and administrative expenses fell to $5.8 million from $6.7 million.
- A new $2.3 million restructuring cost line appeared in the quarter.
- Cash, cash equivalents and marketable securities were $156.2 million at September 30, 2026, with cash runway into the second half of 2029.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.